BioMarin Pharmaceutical (BMRN)
(Real Time Quote from BATS)
$83.92 USD
-0.70 (-0.83%)
Updated Aug 2, 2024 12:38 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BMRN 83.92 -0.70(-0.83%)
Will BMRN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BMRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMRN
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
BMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Amgen (AMGN) Keep the Beat Streak Alive in Q2 Earnings?
Wall Street's Insights Into Key Metrics Ahead of BioMarin (BMRN) Q2 Earnings
Recursion (RXRX) to Report Q2 Earnings: What's in the Cards?
Other News for BMRN
BioMarin Pharmaceutical Larger Than S&P 500 Component Gen Digital
U.S. Food and Drug Administration Approves BioMarin's BRINEURA? (cerliponase alfa) for Children Under 3 Years with CLN2 Disease
BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024
BioMarin gets expanded FDA approval for CLN2 therapy Brineura
BioMarin announces FDA approval of sBLA for BRINEURA